Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nasus Pharma Ltd. ( (NSRX) ) has shared an announcement.
On August 14, 2025, Nasus Pharma Ltd. announced the successful closing of its initial public offering (IPO), raising $10 million through the sale of 1,250,000 ordinary shares at $8.00 each. The company’s shares began trading on the NYSE American LLC exchange under the ticker symbol ‘NSRX’ on August 13, 2025. The proceeds from the IPO will be used to advance the development of Nasus Pharma’s intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies, as well as for general corporate purposes. This IPO marks a significant step in Nasus Pharma’s growth, enhancing its financial resources to further its innovative product development in the pharmaceutical industry.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company based in Tel Aviv, Israel, focusing on the development of innovative intranasal products to treat emergency medical conditions. The company is known for its proprietary powder-based intranasal (PBI) technology, which offers rapid and reliable drug delivery, particularly for acute medical conditions such as anaphylaxis.
Find detailed analytics on NSRX stock on TipRanks’ Stock Analysis page.